Genolution Inc is a Korea-based company principally engaged in the manufacture and distribution of molecular diagnostic equipment and products related to ribonucleic acid interference (RNAi) research. The Company is mainly engaged in the manufacture and sales of nucleic acid extraction reagents for extracting nucleic acids from human samples and automated nucleic acid extraction devices for automatically extracting nucleic acids from samples. The Company also provides RNAi services. The Company distributes its products within domestic market and to overseas markets.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-09-14	₩1,479.00	+2.57%	30,360
26-09-11	₩1,442.00	+2.12%	15,550
26-09-10	₩1,412.00	+0.93%	28,690
26-09-09	₩1,399.00	+1.45%	17,003
26-09-08	₩1,379.00	+0.07%	17,488

End-of-day quote Korea S.E.

More quotes

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. 2026-09-14			5-day change	1st Jan Change
1,479.00 ^KRW	+2.57%		+7.33%	-22.12%

02-18	Kim Ki-ok completed the acquisition of 4.22% stake in Genolution Inc. from HoilBioMed Co., Ltd.	CI
01-20	Kim Ki-ok agreed to acquire 4.22% stake in Genolution Inc. from HoilBioMed Co., Ltd for KRW 1.5 billion.	CI

Market Cap	26.72B 19.84M 17.19M 16.22M 14.72M 27.61M 1.9B 27.81M 194M 74.65M 965M 74.51M 72.86M 3.07B	P/E 2024	-5.89x	P/E 2025	-2.95x
Enterprise Value	22.83B 16.95M 14.69M 13.86M 12.58M 23.59M 1.62B 23.76M 166M 63.8M 824M 63.67M 62.27M 2.62B	EV / Sales 2024	4.38x	EV / Sales 2025	3.23x
Free-Float	66.52%	Yield 2024 *	-	Yield 2025	-

02-18	Kim Ki-ok completed the acquisition of 4.22% stake in Genolution Inc. from HoilBioMed Co., Ltd.	CI
01-20	Kim Ki-ok agreed to acquire 4.22% stake in Genolution Inc. from HoilBioMed Co., Ltd for KRW 1.5 billion.	CI
24-07-30	Genolution Inc. cancelled the transaction announced on May 7, 2024	CI
24-05-06	Genolution Inc. announced that it expects to receive CNY 750.00284 million in funding from RICO Asset Management Co., Ltd. and another investor	CI
24-01-09	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on July 10, 2023.	CI
24-01-09	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on July 10, 2023.	CI
24-01-08	Genolution Inc.'s Equity Buyback announced on July 10, 2023, has expired with 477,003 shares, representing 2.59% for KRW 1,989.17 million.	CI
23-10-13	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on July 10, 2023.	CI
23-07-10	Genolution Inc. announces an Equity Buyback for KRW 2,000 million worth of its shares.	CI
23-07-09	Genolution Inc. authorizes a Buyback Plan.	CI
23-05-15	Genolution Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
23-04-05	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on October 6, 2022.	CI
23-04-05	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on October 6, 2022.	CI

1 day	+2.57%
1 week	+7.33%
Current month	+7.56%
1 month	+7.56%
3 months	+2.42%
6 months	-15.44%
Current year	-22.12%

Genolution Inc. Stock

Stocks

A225220

KR7225220003

Biotechnology & Medical Research

Valuation: Genolution Inc.

Chart: Genolution Inc.

Latest news: Genolution Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Genolution Inc.

Latest insider transactions

Bio Diagnostics & Testing

Financials

Company Profile

Quotes

1 week	1,364	1,479
1 month	1,280	1,479
Current year	957	2,120
1 year	957	2,490
3 years	957	5,140
5 years	957	9,108.91
10 years	957	13,118.81

Manager	Title	Age	Since
Min-Ee Kim CEO	Chief Executive Officer	40	-
Ki-Ok Kim CEO	Chief Executive Officer	71	2006-01-31
Sang-Hoon Kim DFI	Director of Finance/CFO	66	-

Director	Title	Age	Since
Ki-Ok Kim BRD	Director/Board Member	71	2006-01-31
Hak-Soo Lee BRD	Director/Board Member	70	2020-03-19
Min-Ee Kim BRD	Director/Board Member	40	-

Date	Insider	Type	Main position	Quantity	% Market Cap.	Importance
5/24/24	Sang-Hoon Kim	Others	Chief Financial Officer	404,000	2.1053%
5/19/24	Sang-Hoon Kim	Free	Chief Financial Officer	404,000	2.1053%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GENOLUTION INC.	+2.57%	+7.33%	-41.77%	-66.61%	19.44M
IOVANCE BIOTHERAPEUTICS, INC.	+7.67%	+5.35%	+307.93%	+99.35%	3.9B
ADAPTIVE BIOTECHNOLOGIES CORPORATION	+2.40%	+2.06%	+96.51%	+299.03%	3.86B
VERACYTE, INC.	+0.83%	-3.10%	+33.45%	+63.47%	3.29B
CAREDX, INC.	+4.20%	+2.93%	+287.07%	+538.66%	2.6B
BGI GENOMICS CO., LTD.	+2.37%	-0.43%	-33.13%	-30.52%	2.05B
FREENOME, INC.	+4.11%	-8.28%	+41.80%	-	1.54B
SEEGENE, INC.	+1.27%	+1.75%	+22.88%	+40.44%	1.07B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+2.37%	-8.67%	+150.37%	-35.29%	973M
CURIOX BIOSYSTEMS CO., LTD	-0.83%	-6.11%	-6.48%	+70.00%	616M
Average	+2.70%	-0.61%	+85.86%	+108.73%	1.99B
Weighted average by Cap.	+3.37%	-0.27%	+130.08%	+170.83%

	2024	2025
Net sales	7.14B 5.3M 4.59M 4.33M 3.93M 7.37M 508M 7.43M 51.74M 19.94M 258M 19.9M 19.46M 819M	9.4B 6.98M 6.05M 5.71M 5.18M 9.72M 669M 9.79M 68.18M 26.27M 339M 26.22M 25.65M 1.08B
Net income	-6.83B -5.07M -4.39M -4.14M -3.76M -7.05M -486M -7.1M -49.49M -19.07M -246M -19.03M -18.61M -783M	-11.64B -8.64M -7.49M -7.07M -6.41M -12.03M -828M -12.12M -84.41M -32.53M -420M -32.46M -31.75M -1.34B
Net Debt	-8.95B -6.64M -5.76M -5.43M -4.93M -9.25M -637M -9.31M -64.89M -25M -323M -24.96M -24.4M -1.03B	-3.89B -2.88M -2.5M -2.36M -2.14M -4.01M -276M -4.04M -28.17M -10.86M -140M -10.83M -10.6M -446M